In an unusual twist, the talk of the big American College of Cardiology meeting this weekend is likely to be a study whose outcome has already been reported. The trick is figuring out what the outcome means.
Everybody who follows this stuff already knows that Vytorin, a cholesterol drug that combines a statin with a drug [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment